The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GLMD | -62.72% | -99.84% | -72.34% | -100% |
| S&P | +13.22% | +85.17% | +13.11% | +272% |
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Stock market slides are rarely kind to development-stage biopharma companies. Did October's sell-off create any opportunities for investors?
Analysts love this biotech, but should you?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $7.56M | -26.9% |
| Market Cap / Employee | $1.26M | 0.0% |
| Employees | 6 | -25.0% |
| Net Income | -$1.89M | 1.1% |
| EBITDA | -$2.10M | -4.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.44M | -65.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -40.91% | -8.1% |
| Return On Invested Capital | -79.80% | -3.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.94M | -81.9% |
| Operating Free Cash Flow | -$1.94M | -81.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.26 | 0.15 | 0.25 | 0.36 | 15.63% |
| Price to Tangible Book Value | 0.26 | 0.15 | 0.25 | 0.36 | 15.63% |
| Enterprise Value to EBITDA | 6.17 | 10.51 | 6.35 | 5.56 | -3.42% |
| Return on Equity | -49.8% | -49.6% | -54.0% | -46.3% | 24.18% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
